soft tissue sarcoma

Type: Keyphrase
Name: soft tissue sarcoma
First reported Oct 23 2014 - Updated Oct 23 2014 - 1 reports

Funds being raised for Rochester student with rare cancer

ROCHESTER — Soft Tissue Sarcoma is a rare form of cancer. It comprises approximately one percent of all cancers diagnosed, according to the Sarcoma Alliance. Soft tissue sarcoma can occur in the muscles, fat, blood vessels, tendons, fibrous tissues and ... [Published Foster's Daily Democrat - Oct 23 2014]
First reported Oct 21 2014 - Updated Oct 21 2014 - 1 reports

Nanobiotix Secures Approval to Begin Phase II/III Registration Trial in Soft Tissue Sarcoma in Europe

Nanobiotix has received approval from the French National Security Agency for Medicines and Health Products (ANSM) to start its Phase II/III registration trial of its lead product, NBTXR3, in patients with locally advanced Soft Tissue Sarcoma (STS).According ... [Published Individual.com - Oct 21 2014]
First reported Oct 20 2014 - Updated Oct 20 2014 - 2 reports

Blaze wins NCI funding for 'tumor paint' after successful dog study

Seattle-based Blaze Bioscience has nabbed a $1.5 million Small Business Innovation Research (SBIR) Phase II award from the National Cancer Institute (NCI) to continue researching its product, called Tumor Paint BLZ-100, which will be studied in people ... [Published FierceMedicalDevices - Oct 20 2014]
First reported Oct 20 2014 - Updated Oct 20 2014 - 1 reports

21st Century Oncology Welcomes New Oncologist to New York

- Oct. 20, 2014 - YONKERS, N.Y. -- , the nation’s leading provider of cancer care services across multiple modalities, announces that Radiation Oncologist Dhwani Parikh, M.D. has joined the New York practice network.Dr. Parikh has extensive experience ... [Published Prlog - Oct 20 2014]
First reported Oct 20 2014 - Updated Oct 20 2014 - 1 reports

CytRx Announces Publication of Phase 1b/2 Aldoxorubicin Clinical Data in Soft Tissue Sarcoma in Cancer, the Peer-Reviewed Journal of the American Cancer Society

LOS ANGELES, Oct. 20, 2014 /PRNewswire/ -- CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that a paper, titled "A Phase 1b/2 Study of Aldoxorubicin in Patients With Soft Tissue ... [Published PR Newswire: Health - Oct 20 2014]
First reported Oct 20 2014 - Updated Oct 20 2014 - 1 reports

Epizyme reports positive pre-clinical Phase I/II trial results of EPZ in synovial sarcoma

Epizyme has reported positive pre-clinical data from its Phase I/II trial of EPZ-6438 (E7438), its oral, small molecule inhibitor of EZH2, in models of synovial sarcoma, a soft tissue sarcoma that typically affects young adults. ... [Published PBR - News - Oct 20 2014]
First reported Oct 17 2014 - Updated Oct 17 2014 - 2 reports

CytRx appoints Steven A. Kriegsman as chairman of the board

CytRx , a biopharmaceutical R&D company specializing in oncology, has appointed Steven A. Kriegsman, president, CEO and a director of the company, as chairman of the board, effective Oct. 15. He replaces Max E. Link, Ph.D., whose unexpected passing was ... [Published Center Watch - Oct 17 2014]
First reported Oct 17 2014 - Updated Oct 17 2014 - 1 reports

CytRx to Present Data from Global Phase 2b Clinical Trial of Aldoxorubicin in First-Line Soft Tissue Sarcoma at 2014 CTOS Annual Meeting

LOS ANGELES, Oct. 17, 2014 /PRNewswire/ -- CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, announced that data regarding the Company's Phase 2b global clinical trial of aldoxorubicin ... [Published PR Newswire: General Business - Oct 17 2014]
First reported Oct 16 2014 - Updated Oct 16 2014 - 13 reports

Nanobiotix sarcoma drug enters late-stage trial

Nanobiotix has been given the green light by French regulators to start a Phase II/III registration trial of NBTXR3, in patients with locally advanced soft tissue sarcoma.NBTXR3 comprises nanoparticles made of hafnium which can be injected directly into ... [Published Pharma Times - Oct 16 2014]
First reported Oct 16 2014 - Updated Oct 16 2014 - 2 reports

Simple Test May Predict Surgical Wound Healing Complications in Soft Tissue Sarcoma Patients

A simple test called transcutaneous oximetry may be able to predict which patients with soft tissue sarcomas will experience complications while healing from surgery, potentially enabling surgeons to take extra precautions, a study has found. ... [Published Infrosoft - Oct 16 2014]
First reported Oct 08 2014 - Updated Oct 09 2014 - 3 reports

Blaze Bioscience gets SBIR phase II funding for clinical trial of tumor paint BLZ-100 in sarcoma

Blaze Bioscience, a biotechnology company focused on guided cancer therapy, has been awarded a $1.5m Small Business Innovation Research (SBIR) Phase II contract from the National Cancer Institute (NCI) to study Tumor Paint BLZ-100 in patients with soft ... [Published PBR - News - Oct 09 2014]
First reported Oct 08 2014 - Updated Oct 08 2014 - 6 reports

Nanobiotix to receive $1 million milestone after global trial expanded

French nanomedicine company Nanobiotix (Euronext: NANO–ISIN) says that its partner PharmaEngine will join its pivotal trial for NBTXR3 in soft tissue sarcoma to accelerate its development in the Asia-Pacific region.Following the positive pilot Phase I ... [Published Pharma Letter - Oct 08 2014]

Quotes

Laurent Levy, CEO of Nanobiotix commented: "Following the ASCO results, this approval is the second most important step we have accomplished this year as it launches the last clinical phase before potential market authorization. We believe our product, NBTXR3 will offer meaningful clinical benefit for patients with advanced sarcomas where there are serious unmet medical needs."
"Soft tissue sarcoma is quite common in dogs, and the results looked really good," Novak said. "The use of animals that have a naturally occurring tumor is more similar to what's going on in humans. So we see the study in the veterinary setting as a key step for translating it to human clinical studies." Blaze is currently completing a paper about the dog trial for publication
...strive to get all of the tumor during the procedure, often taking large amounts of normal tissue in an attempt to ensure a complete resection. "Our goal with BLZ-100 in sarcoma is to provide surgeons with the ability to see and resect the cancer cells, improving the chances of achieving a complete resection with negative tumor margins" said Dennis Miller, Ph D , Blaze Bioscience's Senior Vice President and Principal Investigator on the NCI contract
...-- CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that a paper, titled "A Phase 1b/2 Study of Aldoxorubicin in Patients With Soft Tissue Sarcoma" has been published

More Content

All (124) | News (96) | Reports (0) | Blogs (25) | Audio/Video (0) | Fact Sheets (0) | Press Releases (2)
sort by: Date | Relevance
EPA Approves Enlist Duo®, Opens Gate to New Wav... [Published Cornucopia Institute - 21 hours ago]
Giant Undifferentiated Oropharyngeal Sarcoma: A... [Published Sexual Development - Oct 24 2014]
Funds being raised for Rochester student with r... [Published Foster's Daily Democrat - Oct 23 2014]
Chronic expanding hematoma with a significantly... [Published 7thSpace - Oct 21 2014]
Nanobiotix Secures Approval to Begin Phase II/I... [Published Individual.com - Oct 21 2014]
Impairment of Lysosomal Activity as a Therapeut... [Published Plosone.org - Oct 20 2014]
Blaze wins NCI funding for 'tumor paint' after ... [Published FierceMedicalDevices - Oct 20 2014]
21st Century Oncology Welcomes New Oncologist t... [Published Prlog - Oct 20 2014]
Blaze Bioscience Announces NCI SBIR Phase II Fu... [Published FierceBiotech - Oct 20 2014]
CytRx Announces Publication of Phase 1b/2 Aldox... [Published PR Newswire: Health - Oct 20 2014]
Epizyme reports positive pre-clinical Phase I/I... [Published PBR - News - Oct 20 2014]
Forum Post: bone biopsy. how to get one if no l... [Published Macmillan Cancer Support - Oct 19 2014]
SMALL CAP MOVERS: Allocate Software investors b... [Published Mail Online UK - Oct 17 2014]
CytRx appoints Steven A. Kriegsman as chairman ... [Published Center Watch - Oct 17 2014]
Morning Buzz: Sarette Therapeutics (SRPT), Rep... [Published Wall Street Pit - Oct 17 2014]
CytRx : Appoints Steven A. Kriegsman as Chairma... [Published 4 Traders - Oct 17 2014]
Epizyme Presents Pre-Clinical Data on EZH2 Inhi... [Published Scottrade - Oct 17 2014]
Epizyme Presents Pre-Clinical Data on EZH2 Inhi... [Published Business Wire Health News - Oct 17 2014]
What types of life science products are most in... [Published CommodityOnline - Oct 17 2014]
CytRx to Present Data from Global Phase 2b Clin... [Published PR Newswire: General Business - Oct 17 2014]
Simple test may predict wound complications aft... [Published Health Canal - Oct 17 2014]
Nanobiotix sarcoma drug enters late-stage trial [Published Pharma Times - Oct 16 2014]
Nanoparticles: A new Solution for the Local Tre... [Published European Medical Device Technology - Oct 16 2014]
Simple Test May Predict Surgical Wound Healing ... [Published Infrosoft - Oct 16 2014]
Simple Test May Predict Surgical Wound Healing ... [Published Newswise - Oct 16 2014]
UPDATE - Nanobiotix gets French go ahead for pi... [Published Proactiveinvestors United Kingdom RSS feed - Oct 16 2014]
Nanobiotix receives first approval to start pha... [Published BusinessPress24 - Oct 16 2014]
Nanobiotix Receives First Approval to Start Pha... [Published Fort Mills Times - Oct 16 2014]
French ANSM Grants Approval for Nanobiotix’s NB... [Published Azonano - Oct 16 2014]
Nanobiotix Receives First Approval to Start Pha... [Published EON Science - Oct 16 2014]
1 2 3 4 5
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
CytRx Announces Publication of Phase 1b/2 Aldox... [Published PR Newswire: Health - Oct 20 2014]
LOS ANGELES, Oct. 20, 2014 /PRNewswire/ -- CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that a paper, titled "A Phase 1b/2 Study of Aldoxorubicin in Patients With Soft Tissue ...
Epizyme reports positive pre-clinical Phase I/I... [Published PBR - News - Oct 20 2014]
Epizyme has reported positive pre-clinical data from its Phase I/II trial of EPZ-6438 (E7438), its oral, small molecule inhibitor of EZH2, in models of synovial sarcoma, a soft tissue sarcoma that typically affects young adults. ...
Epizyme Presents Pre-Clinical Data on EZH2 Inhi... [Published Business Wire Health News - Oct 17 2014]
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today presented pre-clinical data on EPZ-6438 (E7438), ...
CytRx to Present Data from Global Phase 2b Clin... [Published PR Newswire: General Business - Oct 17 2014]
LOS ANGELES, Oct. 17, 2014 /PRNewswire/ -- CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, announced that data regarding the Company's Phase 2b global clinical trial of aldoxorubicin ...
Nanobiotix Receives First Approval to Start Pha... [Published EON Science - Oct 16 2014]
PARIS--(EON: Enhanced Online News)--NANOBIOTIX (Euronext: NANO – ISIN: FR0011341205), a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announced today that it has received approval from the French National ...
1 2 3 4 5

Press Releases

sort by: Date | Relevance
PharmaEngine will join Nanobiotix' pivotal tria... [Published GlobeNewswire: Acquisitions News - Oct 08 2014]
TRACON Pharmaceuticals Initiates Phase 2 Clinic... [Published GlobeNewswire: Acquisitions News - Sep 04 2014]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.